GSK (LON:GSK) Shares Pass Above Two Hundred Day Moving Average – Here’s What Happened

GSK plc (LON:GSK)’s stock price passed above its two hundred day moving average during trading on Thursday . The stock has a two hundred day moving average of GBX 1,613.50 and traded as high as GBX 1,896. GSK shares last traded at GBX 1,848, with a volume of 5,086,101 shares trading hands.

Analyst Ratings Changes

Several equities research analysts have weighed in on the company. Shore Capital restated a “buy” rating on shares of GSK in a report on Thursday, January 8th. Jefferies Financial Group restated a “buy” rating and set a GBX 2,100 target price on shares of GSK in a research note on Wednesday, January 7th. Berenberg Bank raised their target price on shares of GSK from GBX 1,600 to GBX 1,660 and gave the company a “hold” rating in a report on Monday, November 24th. Finally, JPMorgan Chase & Co. reiterated an “underweight” rating on shares of GSK in a report on Wednesday, January 7th. Two research analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat.com, GSK has a consensus rating of “Hold” and an average price target of GBX 1,762.

GSK Stock Down 1.7%

The firm has a 50-day moving average price of GBX 1,816.90 and a two-hundred day moving average price of GBX 1,613.50. The firm has a market cap of £74.55 billion, a price-to-earnings ratio of 13.89, a price-to-earnings-growth ratio of 1.24 and a beta of 0.31. The company has a debt-to-equity ratio of 114.64, a quick ratio of 0.73 and a current ratio of 0.81.

GSK (LON:GSK) last announced its quarterly earnings results on Wednesday, October 29th. The company reported GBX 55 earnings per share (EPS) for the quarter. GSK had a return on equity of 18.08% and a net margin of 8.02%. On average, sell-side analysts forecast that GSK plc will post 175.980975 earnings per share for the current year.

Insider Buying and Selling at GSK

In related news, insider Jonathan Symonds bought 1,650 shares of the company’s stock in a transaction that occurred on Monday, December 22nd. The shares were purchased at an average cost of GBX 1,810 per share, with a total value of £29,865. Also, insider Wendy Becker purchased 441 shares of the business’s stock in a transaction that occurred on Friday, December 19th. The shares were bought at an average price of GBX 1,809 per share, for a total transaction of £7,977.69. Corporate insiders own 0.20% of the company’s stock.

About GSK

GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through two segments, Commercial Operations and Total R&D. The company offers shingles, meningitis, respiratory syncytial virus, flu, polio, influenza, and pandemic vaccines. It also provides medicines for HIV, oncology, respiratory/immunology, and other specialty medicine products, as well as inhaled medicines for asthma and chronic obstructive pulmonary disease, and antibiotics for infections.